KR102438597B1 - 항종양제의 투여 방법 - Google Patents

항종양제의 투여 방법 Download PDF

Info

Publication number
KR102438597B1
KR102438597B1 KR1020217003250A KR20217003250A KR102438597B1 KR 102438597 B1 KR102438597 B1 KR 102438597B1 KR 1020217003250 A KR1020217003250 A KR 1020217003250A KR 20217003250 A KR20217003250 A KR 20217003250A KR 102438597 B1 KR102438597 B1 KR 102438597B1
Authority
KR
South Korea
Prior art keywords
day
compound
days
treatment
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217003250A
Other languages
English (en)
Korean (ko)
Other versions
KR20210016073A (ko
Inventor
켈리 글렌
브라이언 히긴스
그웬 니콜스
카트린 이 팩맨
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20210016073A publication Critical patent/KR20210016073A/ko
Application granted granted Critical
Publication of KR102438597B1 publication Critical patent/KR102438597B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR1020217003250A 2012-03-19 2013-03-15 항종양제의 투여 방법 Active KR102438597B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261612429P 2012-03-19 2012-03-19
US61/612,429 2012-03-19
KR1020197008801A KR20190035957A (ko) 2012-03-19 2013-03-15 항종양제의 투여 방법
PCT/EP2013/055324 WO2013139687A1 (en) 2012-03-19 2013-03-15 Method for administration of an anti tumor agent

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197008801A Division KR20190035957A (ko) 2012-03-19 2013-03-15 항종양제의 투여 방법

Publications (2)

Publication Number Publication Date
KR20210016073A KR20210016073A (ko) 2021-02-10
KR102438597B1 true KR102438597B1 (ko) 2022-08-31

Family

ID=47913395

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020217003250A Active KR102438597B1 (ko) 2012-03-19 2013-03-15 항종양제의 투여 방법
KR1020147026019A Ceased KR20140133583A (ko) 2012-03-19 2013-03-15 항종양제의 투여 방법
KR1020197008801A Ceased KR20190035957A (ko) 2012-03-19 2013-03-15 항종양제의 투여 방법
KR1020167019798A Ceased KR20160089549A (ko) 2012-03-19 2013-03-15 항종양제의 투여 방법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020147026019A Ceased KR20140133583A (ko) 2012-03-19 2013-03-15 항종양제의 투여 방법
KR1020197008801A Ceased KR20190035957A (ko) 2012-03-19 2013-03-15 항종양제의 투여 방법
KR1020167019798A Ceased KR20160089549A (ko) 2012-03-19 2013-03-15 항종양제의 투여 방법

Country Status (21)

Country Link
US (4) US20130245089A1 (https=)
EP (1) EP2827858B1 (https=)
JP (2) JP6224690B2 (https=)
KR (4) KR102438597B1 (https=)
CN (2) CN104203232A (https=)
BR (1) BR112014018135A8 (https=)
CA (1) CA2859940C (https=)
CY (1) CY1118070T1 (https=)
DK (1) DK2827858T3 (https=)
ES (1) ES2593066T3 (https=)
HK (1) HK1204934A1 (https=)
HR (1) HRP20161295T1 (https=)
HU (1) HUE029933T2 (https=)
LT (1) LT2827858T (https=)
MX (1) MX356948B (https=)
PL (1) PL2827858T3 (https=)
PT (1) PT2827858T (https=)
RS (1) RS55250B1 (https=)
RU (1) RU2638795C2 (https=)
SI (1) SI2827858T1 (https=)
WO (1) WO2013139687A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112353762A (zh) * 2013-01-22 2021-02-12 霍夫曼-拉罗奇有限公司 具有改善的生物利用度的药物组合物
EP3459933B1 (en) 2014-04-15 2022-08-24 F. Hoffmann-La Roche AG Solid forms of a pharmaceutically active compound
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
EP3204776B1 (en) * 2014-10-10 2019-09-04 F.Hoffmann-La Roche Ag Methods for personalizing patient cancer therapy with an mdm2 antagonist
AU2017246452C1 (en) 2016-04-06 2021-06-03 The Regents Of The University Of Michigan MDM2 protein degraders
MX388093B (es) 2016-11-15 2025-03-19 Novartis Ag Dosis y regimen para inhibidores de la interaccion hdm2-p53.
US20210122831A1 (en) 2017-03-27 2021-04-29 Noile-Immune Biotech, Inc. Chimeric antigen receptor
CA3052543A1 (en) 2017-03-31 2018-10-04 Novartis Ag Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors
TWI791794B (zh) 2018-03-20 2023-02-11 瑞士商諾華公司 藥物組合
MX2021007391A (es) 2018-12-20 2021-09-23 Novartis Ag Regimenes de baja dosis extendida para inhibidores de mdm2.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100152190A1 (en) * 2008-09-18 2010-06-17 David Joseph Bartkovitz Substituted Pyrrolidine-2-Carboxamides
US20120010235A1 (en) 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101595107A (zh) * 2006-06-30 2009-12-02 先灵公司 能提高p53活性的有取代哌啶及其用途
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100152190A1 (en) * 2008-09-18 2010-06-17 David Joseph Bartkovitz Substituted Pyrrolidine-2-Carboxamides
US20120010235A1 (en) 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"View of NCT01462175 on 2012_03_16", 인터넷 URL: https://clinicaltrials.gov/archive/NCT01462175/2012_03_16 (2012.03.16.)

Also Published As

Publication number Publication date
CY1118070T1 (el) 2017-06-28
ES2593066T3 (es) 2016-12-05
EP2827858A1 (en) 2015-01-28
JP6224690B2 (ja) 2017-11-01
EP2827858B1 (en) 2016-07-20
BR112014018135A2 (https=) 2017-06-20
KR20210016073A (ko) 2021-02-10
US20190328708A1 (en) 2019-10-31
PT2827858T (pt) 2016-09-23
MX2014010586A (es) 2014-09-18
DK2827858T3 (en) 2016-08-22
JP2015510906A (ja) 2015-04-13
HRP20161295T1 (hr) 2016-11-18
US11738003B2 (en) 2023-08-29
CN104203232A (zh) 2014-12-10
BR112014018135A8 (pt) 2021-10-19
HK1204934A1 (en) 2015-12-11
HUE029933T2 (en) 2017-04-28
WO2013139687A1 (en) 2013-09-26
KR20190035957A (ko) 2019-04-03
JP2017061461A (ja) 2017-03-30
PL2827858T3 (pl) 2017-01-31
RU2638795C2 (ru) 2017-12-15
LT2827858T (lt) 2016-10-10
CN110013478A (zh) 2019-07-16
KR20140133583A (ko) 2014-11-19
RS55250B1 (sr) 2017-02-28
RU2014141365A (ru) 2016-05-10
MX356948B (es) 2018-06-20
KR20160089549A (ko) 2016-07-27
US20210069149A1 (en) 2021-03-11
SI2827858T1 (sl) 2016-11-30
US20150126575A1 (en) 2015-05-07
CA2859940C (en) 2020-03-24
US20130245089A1 (en) 2013-09-19
CA2859940A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
KR102438597B1 (ko) 항종양제의 투여 방법
RU2757373C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
ES2535000T3 (es) Composiciones para el tratamiento de cáncer
KR101900520B1 (ko) 복합 조성물
ES3036485T3 (en) Combination comprising everolimus and amcenestrant
BR112019009799A2 (pt) método para tratar câncer em um paciente
Straszkowski et al. Effects of chemotherapy agents used to treat pediatric acute lymphoblastic leukemia patients on bone parameters and longitudinal growth of juvenile mice
Cho et al. Anti-osteoporotic effects of mixed compositions of extracellular polymers isolated from Aureobasidium pullulans and Textoria morbifera in ovariectomized mice
CN117462687A (zh) 一种用于制备预防或治疗骨转移癌药物的组合物及其应用
JP2009539774A (ja) 薬物の投与方法
US11382892B2 (en) Method for administration
Pivot et al. Renal safety of ibandronate 6 mg infused over 15 min versus 60 min in breast cancer patients with bone metastases: a randomized open-label equivalence trial
HK40011479A (en) Method for administration of an anti-tumor agent
CN111407748A (zh) 酪醇在制备治疗脑胶质瘤的药物中的应用
Krempien et al. Combination of irradiation and bisphosphonates in the therapy of bone metastases
WO2014088106A1 (ja) 線維筋痛症の予防または治療薬
EA042139B1 (ru) Фармацевтические композиции и способы лечения рака
NZ788180A (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4